Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ALKS 9072, Low dose · 4 trials · 1 indication
This measure includes all incidences, including those that occurred \>5%.
This measure includes incidences \>5%.
The PANSS scale contains 30 questions, each containing an answer range of 1-7. A total PANSS score can range from between 30 to 210; a higher score indicates a worse disease condition.
| Arm | Type | Description |
|---|---|---|
| ALKS 9072, Low Dose | EXPERIMENTAL | - |
| ALKS 9072, High Dose | EXPERIMENTAL | - |
| ALKS 9072, Low | EXPERIMENTAL | - |
| ALKS 9072, High | EXPERIMENTAL | - |
| ALKS 9072 | EXPERIMENTAL | - |
| Placebo | PLACEBO_COMPARATOR | - |
| ALKS 9072, Med dose | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| ALKS 9072, Low Dose | DRUG | Intramuscular injection, given monthly |
| ALKS 9072, High Dose | DRUG | Intramuscular injection, given monthly |
| ALKS 9072, Low | DRUG | IM injection, given monthly |
| ALKS 9072, High | DRUG | IM injection, given monthly |
| ALKS 9072 | DRUG | Intramuscular (IM) injection, 441 mg or 882 mg given monthly |
| Placebo | DRUG | Placebo for IM injection, given monthly |
| ALKS 9072, Med dose | DRUG | IM injection, given monthly |
Inclusion Criteria: * Completed the treatment period of Study ALK9072-003EXT * Continues to require chronic treatment with an antipsychotic medication * Continues to reside in a stable living situation * Continues to have an identified reliable informant Exclusion Criteria: * Abnormal clinical la...
ALKS 9072 is an investigational small molecule being developed for the treatment of schizophrenia. It is a low-dose formulation studied in patients with this psychiatric condition. The drug has completed clinical trials, including Phase 3 studies, but it is not yet approved and remains in clinical development.
ALKS 9072 is a small molecule, but its specific molecular target has not been disclosed in the available information. The drug is being studied for its efficacy and safety in treating schizophrenia, a psychiatric disorder. Without a stated target, the mechanism of action is not described here.
ALKS 9072 is developed by Alkermes plc, a biopharmaceutical company traded on the NASDAQ under the ticker ALKS. The company has conducted clinical trials of this drug for schizophrenia, including Phase 3 studies, and is the sponsor of the research.
ALKS 9072 is in Phase 3 clinical development for schizophrenia. It has completed Phase 3 trials, including a study with 623 participants, but it is not FDA approved. The drug is still investigational and has not yet received regulatory approval for marketing.
ALKS 9072 has been studied in four completed clinical trials for schizophrenia. These include NCT01469039, a Phase 3 efficacy and safety study with 623 participants, and NCT01626456, a long-term safety study with 478 participants. All trials are completed, with no active studies ongoing.
Yes, ALKS 9072 is also known as aripiprazole lauroxil, ALKS 9070, or ARISTADA. Clinical trials for ALKS 9072 explicitly reference these alternative names, indicating they refer to the same drug. This information helps identify the drug across different naming conventions.